Celgene Dips Into The Antibody Well Once More, Partners With Sutro
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.